Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

94

Participants

Timeline

Start Date

February 9, 2017

Primary Completion Date

January 1, 2021

Study Completion Date

December 14, 2022

Conditions
Cervical Cancer
Interventions
DRUG

Pembrolizumab

200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.

RADIATION

Brachytherapy

Radiation is done for standard clinical care purposes.

DRUG

Cisplatin

40 mg of chemotherapy drug will be given weekly for 5-6 weeks.

Trial Locations (8)

21287

Johns Hopkins, Baltimore

22042

INOVA Fairfax Hospital, Falls Church

22908

University of Virginia, Charlottesville

23298

Virginia Commonwealth University, Richmond

28204

Levine Cancer Institute, Charlotte

36604

University of South Alabama Mitchell Cancer Institute, Mobile

63108

Washington University, School of Medicine, St Louis

73104

University of Oklahoma, Oklahoma City

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Linda R Duska

OTHER

NCT02635360 - Pembrolizumab and Chemoradiation Treatment for Advanced Cervical Cancer | Biotech Hunter | Biotech Hunter